A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems
Pharmacokinetics, Safety and Tolerability of BI 425809 (Iclepertin) Following Oral Administration in Male and Female Participants With Different Degrees of Renal Impairment (Severe, Moderate and Mild) Compared With Matched Male and Female Participants With Normal Renal Function (an Open-label, Non-randomised, Single-dose, Parallel, Individual-matched Design Trial)
Sponsor: Boehringer Ingelheim
This PHASE1 trial investigates Renal Insufficiency and is currently completed. Boehringer Ingelheim leads this study, which shows 12 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE1
▶ Show 7 earlier versions
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE1
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE1
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE1
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE1
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE1
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE1
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE1
First recorded
Feb 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .